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Today, there are over 250 drugs being used to cure over 100 different types of cancer. We hypothesize that 
one of the drugs already being used in cancer treatment will either show positive or negative growth when 
applied specifically to glioblastoma, a type of brain tumor with poor prognosis. Using the fruit fly, 
Drosophila melanogaster, and 150 tyrosine kinase inhibitors, we can induce tumors and track their growth 
in response to the drugs. This would open the doors to researching similarities between drugs present in 
hundreds of chemical libraries. Additionally, the drugs that prove successful through the screenings could 
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Chapter 1  
 
History of Drosophila 
Drosophila has been proven to be a useful model organism in the scientific field since it 
was first used in 1901 by Thomas Hunt Morgan (Jennings, 2011). Jennings states in her 
research that Morgan, along with many other scientists, found Drosophila more 
beneficial than vertebrae models for a number of reasons, including they are easy and  
inexpensive to culture in laboratory conditions, have a much shorter life cycle of about 12 
days, represented in Figure 1, and they produce large numbers of externally laid embryos 
that can be genetically modified. Morgan used the defining of genes and ability to 
establish that they were on the chromosomes to further define the theory of inheritance 
that was proposed by Gregor Mendel (Jennings, 2011). It was this redefining that led 
Morgan to receive The Nobel Prize of Physiology or Medicine in 1933 for “his 
discoveries concerning the role played by the chromosome in heredity” (“Nobel Prize and 
Literature”, 2018). This Nobel Peace Prize opened the doors to different research that 
could be conducted using Drosophila, and it was this continuation of research that went 
on to win many other awards of their own. This is demonstrated through the findings of 
Jeffery C. Hall, Michael Rosbash and Michael W. Young, who in the 1980s discovered 
the molecular mechanism that controls circadian rhythms using this model organism 
(Huang, 2018). Areas of their research concerned the rapid reproduction of recombinant 
DNA, which allowed them to both characterize and clone the Drosophila clock gene 
named period independently. It is this rich legacy of past research that allows this model 
organism to be used for comparisons to continually be made between different biological 
diseases as well as other physiological differences.  
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Fig. 1. Lifecycle of Drosophila Melanogaster: For both 
male and female flies, they go through 5 different growth 
stages, starting with the embryo and ending with pupa. 
Image from: Creative Diagnostics, 2009-2018. 
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Comparisons Between Drosophila and Humans 
     Besides the ability to easily induce desired genetic pathways, Drosophila also makes a 
good model organism due to it sharing 70% of disease genes with humans (Read et al. 
2009). Drosophila has approximately 13,600 genes in its genome, which was sequenced 
for the first time in 2000 (Mark et al. 2000). Of these 13,600 genes, there was a separate 
study completed that looked at the 929 human disease genes that were associated with at 
least one mutant allele discovered in Drosophila’s own genome (Reiter et al. 2001). The 
OMIM, or Online Mendelian Inheritance in Man, was used as the human comparison 
group. In Reiter et. al. research they found that of the 929 OMIM genes, 714 contain 
highly similar (E ≤10−10) cognates in Drosophila (77%). The researchers created a 
database, appropriately named Homophila, to build the connection between Drosophila 
and humans, allowing for the variety of many successful experiments to be conducted in 
the future. A subset of shared genes are illustrated in Figure 2, which represent the 
different cancer types that can be a modelled using Drosophila.  
     In the past, other research has been conducted that focused on the genetic comparisons 
between Drosophila and human disease (Fortini et al. 2000; Rubin et al. 2000). Although 
these studies all proved successful, they were a more restrictive study than that performed 
by Reiter et. al., only looking at a subset of 289 linked genes. Fortini and Rubin’s 
research does not take into account the remaining 425 genes (when compared to the 
linked 714 in Reiter’s study), nor do they examine the vast possible genetic effects of the 
found 289 genes. Fortini and Rubin in their studies further solidified the genetic 
connection between Drosophila and humans, but a much wider gene pool was necessary 
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Figure 2. Illustration of tumor expression in Drosophila. Tumors ranging from Imaginal Disks, 
Brain, Muscle, and Haemo-lymph tumors can be expressed. These can be further divided into 
sub-tumors as listed on the right along with the type of pathways used for each. Showcases 
how Drosophila is a top-tier model organism for expressing the wanted tumors. Figure from 
Villegas, 2017.  
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Inducing Glioma in Drosophila   
The model of glioma that can be replicated repeatedly in Drosophila is useful in studying 
the possible causes, as well as changes that can act as inhibitors to the tumor growth. The 
fly brain is composed of two dorsal hemispheres and the ventral nerve cord, that forms 
the central nervous system of the fly. The CNS is mainly comprised of neuron and glia 
that make up ~10% of cells in the fly CNS (Witte et al., 2011). This substantial 
percentage gives good insight into what makes glioblastoma so malignant, given the fact 
it is a glial driven tumor.  Other areas that Witte, Jeibmann, etc. cover in their research 
are the pathways that can be induced in Drosophila to effectively produce glioma. They 
found promising molecular targets for therapeutic intervention included the tyrosine 
kinase receptors epidermal growth factor receptor (EGFR), platelet-derived growth factor 
receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR) and their 
downstream signaling cascades, the phosphatidylinositol 3-phosphate kinase (PI3K)/AKT 
and Ras/mitogen-activated protein kinase pathway (Witte et al. 2009). Additionally, it 
was found that using the GAL4-UAS system proved the most effective when testing 
possible pathways to inhibit glioma via different measures, and this is shown in Figure 3. 
Although this research does exhibit the GAL4-UAS system as an effective pathway, it 








Figure 3. Optical projections of whole brain-ventral nerve cord complexes from late 3rd instar 
larvae approximately 130 hr AED, displayed at the same scale. Dorsal view; anterior up. Each 
brain is composed of 2 symmetrical hemispheres attached to the ventral nerve cord (VNC). In 
repo>dEGFRλ;dp110CAAX larvae, both brain hemispheres and the VNC are enlarged and 
elongated relative to other genotypes. Figure by Read et al., 2009.  
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The P13K Ras Pathway  
     The three core signaling pathways that are commonly activated in glioma patients are 
the tumor protein p53 [p53] pathway, the receptor tyrosine kinase/Ras/phosphoinositide 
3-kinase signaling pathway, and the retinoblastoma pathway (Davis, 2016). Despite these 
separate pathways, the EGFR-Ras and PI3K pathway continues to be one of the most 
effective models, as shown in Figure 4. The mutation or amplification of the Epidermal 
Growth Factor Receptor (EGFR) tyrosine kinase continually shows the most frequent 
genetic damage in gliomas, as stated in Read et al. research concerning this specific 
pathway. The network EGFR-Ras/ PI3K pathway coordinately stimulates oncogenic 
behaviors, such as, cell cycle entry and progression, protein translation, and inappropriate 
cellular growth and migration. The article states that it is these behaviors exhibited in the 
coactivation of these pathways that creates tumor-like growths that mimic human glioma, 
which is what makes it so useful in a laboratory setting. When PI3K Ras pathway was 
activated using the repo-Gal4 driver, it induced an accumulation of ~50-fold excess glia 
(Read et al. 2009). In spite of their being different pathways initiated to produce glioma, 
in Read et al. study they found glial-specific coactivation of EGFR-Ras and PI3K 
stimulated glial neoplasia, giving rise to CNS enlargement and malformation, neurologic 
defects, and late larval lethality. 
 
  




Figure 4. Overview of the PI3K/AKT/mTOR pathway and drug targets. Activating nodes (PI3K, AKT, 
PDK1, mTORC1 and mTORC2) and negative regulators (PTEN, TSC complex) are highlighted. Interaction 
with RAS and LKB1/AMPK pathways is also displayed.  
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Tyrosine Kinase Function  
Tyrosine kinases are a family of enzymes, which use ATP to catalyze phosphorylation of 
select tyrosine residues in target proteins. It is these enzymes, through covalent post-
translational modification, that act as a key component of normal cellular communication 
and maintenance of homeostasis (Paul & Mukhopadhyay, 2004). Some of these cellular 
functions include: cell proliferation, differentiation, migration, metabolism and 
programmed cell death. Paul and Mukhopadhyay go on in their research of tyrosine 
kinases to state that it is the ligand binding to the kinase’s extracellular domain that 
triggers a response, as seen in Figure 5. These ligands are extracellular signal molecules 
(e.g. EGF, PDGF etc.) that induce receptor dimerization, which is a chemical reaction 
that joins two molecular subunits, forming a dimer (Chemistry LibreTexts, 2017) 
 
There are two separate classifications of Tyrosine Kinases, either Receptor Tyrosine 
Kinase (RTK) or non-receptor tyrosine kinase (NRTK). The RTK are cell surface 
transmembrane receptors that also possess kinase activity. Paul and Mukhopadhyay 
found in their research that the RTK are ligand specific, contain a single pass 
transmembrane hydrophobic helix and a cytoplasmic portion with a tyrosine kinase 
domain. NRTK are cytoplasmic proteins, that contain a kinase domain and possess 
several additional signaling or protein-protein interacting domains (Paul & 
Mukhopadhyay, 2004). It was found that the activation mechanism of NRTK is more 
complex than that of RTK, which they hypothesized made the RTK more frequently 
activated.  
 
Tyrosine kinases activity are tightly regulated in normal cells, but they have the ability to 
acquire transforming functions due to mutation(s), overexpression and autocrine 
paracrine stimulation, leading to malignancy (Paul & Mukhopadhyay, 2004). It is these 
different functions that the kinase takes on that allow it to represent a major portion of the 
oncoproteins that play a powerful role in the plethora of cancers, which includes glioma. 
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Figure 5. Mechanism of action of tyrosine kinase. 1. Receptor expression at membrane claveola 2. Ligand 
binding occurs 3. Hetero/homodimerization leads to tyrosine kinase activation and tyrosine 
transphosphorylation 4. Signal transduction throughout the cell 5. Receptor internalization 6. Receptor 
activates response of either degradation or re-expression. Figure by Paul & Mukhopadhyay, 2004. 
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Tyrosine Kinase Role in Cancer   
To ensure normal tissue patterning in an organism, there must be tight control of cell 
proliferation and morphogenesis in conjunction with programmed apoptosis. It is when 
imbalances occur within these cell signals that oncogenesis can occur (Sangwan & Park, 
2006). As stated in earlier research (Mukhopadhyay & Paul, 2004), it is the more 
frequently activated RTKs that have the potential to cause dimerization to the kinases, 
and this change in conformation leads to activation of the kinase and 
transphosphorylation of the receptor on specific tyrosine residues. The phosphorylated 
tyrosine residues are a critical aspect because they provide docking sites on the receptor 
for signaling proteins, and it is these signaling proteins that act to relay the signal from 
the receptor into the cell. When these signaling pathways become altered through 
mutations or chromosomal translocation, the RTKs can deliver a continuous or enhanced 
signal, forming it into a potent oncogene (Sangwan & Park, 2006). As of 2001, 58 genes 
encoding RTKs have been identified in the human genome, 30 of which have been found 
to be dysregulated in human cancers (Blume-Jensen & Hunter, 2001). Different 
discovered tyrosine kinases inhibitors are shown in Figure 6. 
 
Together with these behaviors, Sangwan and Park (2006) found that growth-factor 
stimulation within a cell also aids in producing oncogenic behaviors. It is the non-
scheduled expression of these growth factors that may result in a constant stimulation of 
cell growth in addition to a block in apoptosis. The combination of the mis-regulated 
RTKs and growth factors plays a critical role in regulating the tumor microenvironment, 
by enhancing both the proliferation and invasion by tumor cells. This invasion of tumor 
cells can form lung, breast, and brain cancer, and Sangwan & Park in their research go to 
explain how the pathways are initiated, and also possible routes that can be taken to halt 
the tumor progression in its track.  
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Figure 6. These are structures of some of the important kinase inhibitors discovered so far. Figure by 
Grant, 2008.  
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Tyrosine Kinase Expression in Drosophila  
Through the sequencing completed by the Human Genome Project, it was found that the 
human genome contains 90 tyrosine kinases (Robinson et al., 2000). Of these 90 tyrosine 
kinases, 58 are the receptor types (RTKs). Of this large amount of RTKs present in the 
human genome, only 20 RTKs have been identified in the Drosophila genome. Just like 
what has been found in human kinases, these different receptors share many of the same 
effectors and their hierarchical organization is retained in biological contexts (Sopko & 
Perrimon, 2013). While in their research they may have found this to be true for the 
identified Drosophila tyrosine kinase receptors, very little is still known for 
approximately half of them.  
 
Of the many pathways that RTKs can signal in the Drosophila genome, the one most 
commonly linked to glioma is the Epidermal Growth Factor Receptor (EGFR). EGFR 
plays a multitude of roles inside the genome, such as dorsal/ventral patterning of the 
embryonic ectoderm, establishment of neuroectoderm, wing development, photoreceptor 
differentiation, and the specification of muscle precursors (Sopko & Perrimon, 2013). It 
is able to signal these specific pathways by predominantly mediating short-range 
signaling that is restricted to cells producing EGF or to cells positioned 1-2 cells away. A 
pathway that falls into this category is the Ras/Raf/MEK/ERK pathway, showcased in 
Figure 7. There are four EGFR ligands in Drosophila: Spitz, Keren, Gurken, and Vein, 
and Sopko & Perrimon found in their study that all four play a critical role in the 
signaling of the pathway. By monitoring these different ligands and sub-pathways in 
EGFR, Sopko and Perrimon opened up the research field to possibly triggers or onsets of 








Figure 7. Activation of Ras/Raf/MEK/ERK signaling pathway. RTK, receptor tyrosine kinase; 
SOS, mammalian son-of-sevenless; Shc, homology 2 domain-containing protein; MEK, 
mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase. 
Figure by Yang & Yang, 2017.  
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Success of Tyrosine Kinase Inhibitors with Glioma  
The modes of oncogenic activation can be targeted using different approaches for 
tyrosine kinase inhibition, such as, small molecule inhibitors, monoclonal antibodies, heat 
shock proteins, immunoconjugates, antisense and peptide drugs (Mukhopadhyay, Paul 
2004). The small-molecule compounds that inhibit the kinase domain have recently 
changed clinical practice for several cancers. Lapatinib has shown positive effects in 
HER2-positive metastatic breast cancer (Geyer et al., 2006); sunitinib positively 
influences metastatic renal-cell carcinoma (Motzer et al., 2007); and sorafenib is 
beneficial in carcinoma treatment due to it inhibiting the targeted kinase domain (Joseph 
et al., 2008). Taking this knowledge on the kinase inhibitors that work, De Witt Hammer 
(2010) systematically reviewed the efficacy, toxicity, and tissue analysis of small-
molecule kinase inhibitors in adult patients with glioblastoma as reported in published 
clinical studies. De Witt Hammer also determined which kinases have been targeted by 
the inhibitors used in these studies, by using publications from a MEDLINE search. From 
the search, 60 studies qualified for inclusion, and 2385 glioblastoma patients receiving 
kinase inhibitors could be evaluated. The extracted data included radiological response, 
progression-free survival, overall survival, toxicity, and biomarker analysis. This data 
could be analyzed to determine the overall effects of kinase inhibition from past studies, 
by looking at the effects it showed on the patients during and after treatment.  
 
De Witte Hammer found through analysis that (i) efficacy of small-molecule kinase 
inhibitors in clinical studies with glioblastoma patients does not yet warrant a change in 
standard clinical practice and (ii) 6 main kinase targets for inhibitors have been evaluated 
in these studies: EGFR, mTOR, KDR, FLT1, PKCβ, and PDGFR. Although in this study 
the promise of kinase inhibitors being effective in cancer treatment was not strong, De 
Witte Hammer overlooks the fact that there are many limitations to his study. Some of 
these limitations include, not having a control group, small sample sizes, and many of the 
60 studies were not designed to determine the efficacy of therapy. The efficacy of the 
therapy is especially important, because by not having that the pathobiology of the drug 
may not be accurately studied in glioblastoma patients, along with the inhibitor may have 
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failed to inactivate the target in glioblastoma cells. Knowing the efficacy would aid to 
ruling out these errors and producing more accurate studies in the future.  
 
Different from De Witte Hammer’s study (2010), Mellinghoff et al. (2012) looked more 
specifically at how kinase inhibitors perform as glioblastoma drugs, specifically when 
targeting the PI3K pathway. Throughout their study they look at results from clinical 
trial, the structure of the human genome, and techniques that can be applied to 
glioblastoma to halt tumor growth. The clinical study looked specifically at mTOR, 
which was the first member of the PI3K pathway for which a clinical grade inhibitor 
became available, and its effect on patients with PTEN-deficient, recurrent glioblastoma 
(Podsypanina et al., 2001). After 1-2 weeks, the effect that inhibition of mTOR had on 
glioblastoma was analyzed, and it was found that although there was reduction of 
neoplasia, it was not enough to cause effective change on the tumor. Although these 
results do not seem promising, it must be taken into account that the information was 
preliminary because tumors with the most informative genotype(s) and strong basal 
pathway activation were generally underrepresented in the studies and because of 
difficulties to assemble a sufficient drug-naive “control” tumor sample (Mellinghoff et 
al., 2012). In their study, Mellinghoff et al. (2012) also talk about factors that would 
increase the therapeutic window of individual kinase inhibitors. It is stated that these are 
different dosing schedules (e.g., intermittent or “pulsatile” dosing) (Shah et al. 2008) and 
isoform-specific (e.g., PI3K) or mutant-specific (e.g., BRAF) compounds. The different 
dosage levels effectiveness can be represented through cytotoxicity, and the results are 
shown in Figure 8. The different dosage levels are the strongest candidate for positive 
results, given it was this fact that was also highlighted in De Witte Hammer’s (2010) 
study of kinase inhibitors with glioblastoma.  
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Figure 8. (A) The results establish a relationship between concentration and 
treatment duration with different kinase inhibitors. Cytotoxicity approached 100 
percent in cells exposed continuously to 0.5 or 1 nM dasatinib (left) but was 
substantially diminished with shorter exposure times. Similar results were observed 
using concentrations of imatinib (1 μM) (right). (B) Assessment of BCR-ABL kinase 
activity in K562 cells through analysis of phospho-CRKL and phospho-STAT5 following 
treatment for 20 min with varying concentrations of dasatinib (left) and imatinib 
(right). Figure from Shah et al. 2008. 
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Glioma Treatment  
 
Surgery 
Standard treatment of glioblastoma includes maximal safe surgical resection, followed by 
concurrent radiation with temozolomide (TMZ) (Temodar®), an oral alkylating 
chemotherapy agent, and then adjuvant chemotherapy with TMZ (National 
Comprehensive Cancer Network [NCCN], 2015). Although surgically removing the 
tumor would seem like a promising therapy, extensive and complete surgical resection of 
glioblastoma is difficult because these tumors are frequently invasive and are often in 
eloquent areas of the brain, including areas that control speech, motor function, and the 
senses (Davis, 2016). In the study conducted by Kuhnt et al. (2011), they focus on how 
the more total resection for the patients possible, the more beneficial surgery will be in 
glioblastoma therapy. They came to this conclusion by having 135 glioma patients 
undergo tumor resection aided by 1.5T intraoperative MRI (iMRI) and integrated 
multimodal navigation. The media survival was 14 months for patients who underwent an 
extent of resection ≥98%, which is a significant improvement in patient survival. Kuhnt 
et al. (2011) in their study came to the conclusion that results like this can be achieved 
with iMRI and an intraoperative update of navigation data, along when performed on 
patients <65 years of age. Although, Kuhnt et al. (2011) study showed promising results, 
the prognosis for patients with GBM remains poor, with a median survival of 15 months 
(Thakkar et al., 2014). In conclusion, both Thakkar et al. (2014) and Kuhnt et al. (2011) 
found that patients with a lower age and higher performance status experience longer 
survival.    
 
Chemoradiation 
Chemoradiation as means of glioblastoma treatment has been seen to produce more 
promising results compared to chemotherapy and radiation alone. Although it is one of 
the most popular choices of glioblastoma therapy, usually occurring around 4 weeks after 
surgery, it holds the potential to cause more consequences than advantages. Shih and 
Batchelor’s study (2017) analyzed the different techniques of chemoradiation practiced 
(Adjuvant radiotherapy, treatment target, Intensity-modulated RT, etc.) and stated the 
similar limitations found in each of them. It was found that the similar consequences of 
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chemoradiation on glioblastoma include radiation-induced gliomas, neurocognitive 
toxicity, RT-induced leukoencephalopathy, and endocrinopathies (Shih & Batchelor, 
2016). Other side effects do occur because of chemoradiation, but they are more specific 
to the route of chemoradiation chosen. Together with all these side effects, it was found 
that the survival rate of patients was still low, with at 17 months after treatment 72% of 
patients developed recurrent glioblastoma (Milano et al, 2010). Comparing Shih and 
Batchelor’s (2016) findings to present chemoradiation practice, the adequate dose of 
chemoradiation necessary to cause a high survival rate with low cytotoxicity levels is 
required to maximize the survival benefit. Furthermore, these studies done in the past on 
glioblastoma chemoradiation treatment, which included the benefits and limitations of it, 
showed that further therapy options must be taken either before or after this to ensure an 
increase in overall patient survival.  
 
Temozolomide  
Chemoradiation started showing much higher patient survival rates and less lethal side 
effects when it contained Temozolomide (TMZ), rather than simple radiation alone, 
shown in Figure 9. A separate study was conducted to test and analyze the results of 
TMZ used in clinical practice, and the results from it were promising (Stupp et al., 2005). 
This study was conducted with 573 patients who randomly received radiotherapy alone or 
radiotherapy plus continuous daily temozolomide, followed by six cycles of adjuvant 
temozolomide. At the median follow-up of 28 months, the median survival was 14.6 
months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone 
(Stupp et al., 2005). The two-year survival rate was 26.5 percent with radiotherapy plus 
temozolomide and 10.4 percent with radiotherapy alone. These results were clinically 
beneficial and showed statistically significant survival benefit with minimal additional 
toxicity.  
 
Another study looked at the combinatorial effect of high-linear transfer radiation (high-
LET) combined with Temozolomide, versus with conventional radiation like the study 
above. Glioblastoma in treatment is known as a radioresistant tumor, meaning that even 
when treated with conventional radiation the survival rates are still low. Barazzuol et al. 
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(2012), believe that by using the new technology of high-LET combined with 
Temozolomide on glioblastoma tumors, then this will show a much greater success rate 
than what conventional radiation has shown in the past. To accomplish this, they tested 
these combinations on four different human glioblastoma strains and analyzed their cell 
survival, DNA damage and repair, and cell growth (Barazzuol et al., 2012). The results 
from this study did not find any additive effects between high-LET and TMZ, but did 
present data that supports the notion that the cytotoxic effects of TMZ and high-LET are 
not likely to be correlated. This recognizes and supports past data that TMZ cytotoxicity 
needs one or two cell divisions before DNA damage can be recognized. The cytotoxicity 
of TMZ must be considered in both experimental or clinical procedures, and this data 
further supports the positive effects of TMZ when in combination with either 
radiotherapy or other chemotherapy drugs.  
 
Temozolomide acts through DNA alkylation, and this analysis led to another strong 
predictor of patient-related outcomes: the methylation of the MGMT gene (Stupp et al., 
2009). Methylated (not activated) MGMT exhibit compromised DNA repair, so when 
MGMT becomes activated it can interfere with the effects of treatment. Radiotherapy and 
alkylating chemotherapy exert their therapeutic effects by causing DNA damage, 
cytotoxicity, and triggering apoptosis. Therefore, the expression of methylated MGMT is 
beneficial for patients undergoing temozolomide chemotherapy and radiation. In this 
study conducted by Stupp et al. (2009), the methylation of MGMT was a strong predictor 
of better outcomes for temozolomide treatment. 
 
  




Figure 9. Results from clinical trial of patient treated with Radiotherapy plus Temozolomide vs. those 
treated with Radiotherapy alone. The results showed a much higher probability of survival over a 42 
month time span for those treated with Temozolomide vs. without. Figure from Stupp et al., 2005.  
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Chapter 2  
Materials and Methods  
Blind Study 
The first step in completing this combinatorial drug screen was determining which 
Tyrosine Kinase Inhibitors proved to be the most successful. This was done by 
completing a blind study over the course of the semesters. Blind studies are ones that can 
be utilized in both the laboratory setting and also in clinical trials of medicine. Blind 
studies by definition are studies done in which the subjects involved in the study do not 
know which experimental condition they are receiving (Clinical Trials and Screening, 
2020). There are both double-blind and single-blind studies that can be conducted, but in 
the case of the drug screen it is only a single-blind study. In dealing with the Tyrosine 
Kinase Inhibitors, the researchers are unaware of which Tyrosine Kinase Inhibitor they 
are testing. It is done so by having the drugs named and labeled as a letter and numerical 
value (i.e. A11). This blinding is especially important in experimental usage due to its 
ability to prevent bias from influencing the results (Clinical Trials and Screening).  
 
Many of the blind studies that are in the field of treating cancer, specifically with 
glioblastoma, are experimented on the clinical trial side of medicine. These experiments 
are done by recruiting a group of people that will allow for external validity to be applied 
and who’s consent is properly given. An example of one of these blind studies took place 
in 2017 with the combined use of TMZ with Rindopepimut (Weller et al., 2017). 
Rindopepimut is a vaccine that targets the EFGR deletion mutation EGFRvIII. It does so 
due to it being composed of a an EGFRvIII-specific peptide conjugated to keyhole limpet 
haemocyanin (NCI Drug Dictionary). In this study patients with newly diagnose 
EGFRvIII-expressing glioblastoma were treated with either Rindopepimut plus TMZ or 
Rindopepimut plus control over the course of 6-12 cycles of treatment (Weller et al., 
2017). The results were collected using a randomized, double-blind trial, meaning that 
neither the subject nor the researcher knew what treatment they were receiving. At the 
end of the trial when compared to the control group, it was discovered that Rindopepimut 
did not increase the survival rate in patients diagnosed with glioblastoma.  
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A successful blind study which was done at the laboratory level looked at drug resistance 
in Mycobacterium tuberculosis with the drugs isoniazid (INH) and rifampin (RMP). In 
this study consecutive isolates of Mycobacterium tuberculosis were coded and sent to two 
external laboratories for genotypic analysis of INH and RMP resistance by PCR-single-
strand conformation polymorphism (SSCP) analysis (Enriquez et al. 1997). The study 
was considered blind given that the external laboratories were not aware of which of the 
two drugs they would be testing, which allowed for no bias to negatively impact the 
results. Through this study it was found that resistance can be accurately detected for 
both INH and RMP when the study is limited to analyzing four main genetic regions 
(Enriquez et al. 1997).  
    
Dissection and Mounting 
The phenotypes present in the fruit fly will be assessed from the larval to the pupae stage 
to monitor growth regulation and cell proliferation in the adult brain from the third instar 
larval stage following standard protocol. Dissection and mounting of the adult brain will 
be necessary to track and get clear images of the progression of the tumor. Drosophila 
larval brains are useful in modeling human brain degenerative diseases, mapping 
neuronal circuitries in adult brains, and studying the molecular and cellular basis of 
higher brain functions (Tito et al. 2016). In this drug screen dissection of the brain was 
done on the third day of the larvae’s exposure to the specific drug. These drugs can either 
be (a) a Tyrosine Kinase Inhibitor, (b) TMZ, or (c) Tyrosine Kinase Inhibitor plus TMZ. 
The protocol calls for use of a Petri Dish and .55 forceps to ensure that a majority of the 
eye and tracheal tissues normally associated with the brain are removed so no 
interference is encountered in the later imaging steps (Tito et al. 2016).  
 
The method used for proper dissection was to gently hold the larval body with one pair of 
forceps, and with a second pair of forceps, hold the larval mouth hook. Pull the two pairs 
of forceps apart gently to cause the mouth hook to detach from the body, allowing to the 
brain to be isolated (Wu & Wu, 2006). Once brains are properly dissected, place them in 
a 150μL phosphate-buffered saline (PBS) and 50μL Para-formaldehyde (PFA) solution to 
fix for 20 minutes. Next add 1mL of cold 1xPBST (3.2 mM Na2HPO4, 0.5 mM NaH2PO4, 
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1.3 mM KCl, 135 mM NaCl, 0.05% Triton X-100) and place on a rotator for 10 minutes. 
After ten minutes, vacuum out PBST and repeat the wash two more times.  
 
For mounting there were no antibodies used, so a primary and secondary stain were not 
completed for the samples. Mounting was completed on a glass slide using .55 forceps to 
isolate the unwanted tissues from around the brains. Once properly isolated, the brains 
were coated in Vectashield to inhibit the rapid photobleaching of fluorescent proteins and 
fluorescent dyes (VECTASHIELD®, 2020). The brains were then organized in a line, a 
cover slip was placed properly on top, and nail polish was used to inhibit the cover slip 
from sliding. Mounted slides were then labeled and placed in a -20˙C freezer until 
imaging could be completed.  
 
Imaging 
The samples taken from the Drosophila models, once properly dissected and mounted, 
will be scanned in the Laser Confocal Scanning microscope. The adult flies will be 
photographed by using Olympus Bx51 Florescence microscope or Zeiss Apotome. The 
images that are generated from these microscopes will be used to more clearly track the 
growth of the tumor as well as be analyzed for statistical significance using Image J 
programming. Images will be analyzed based on both their glial cell presence and size 
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Layout of Drug Screen  
 
Tyrosine Kinase Inhibitors 
To analyze the effects of Tyrosine Kinase Inhibitors in treating glioblastoma, dissection, 
mounting and imaging of the brain were completed. The stocks of Pteni; Rasv12, and 
Repo Gal4 UAS-GFP served as controls, and the F1 larvae from the Pteni;Rasv12x Repo 
GFP cross constituted the experimental samples in which glioma was induced in the 
larval CNS. All inhibitors were first tested at the 300μL dose. By following the protocol 
that is demonstrated in Figure 1, the brains were analyzed for two characteristics: (a) the 
number of glial cells left after treatment, and (b) the change in overall size of the brains. 
A successful treatment of Tyrosine Kinase Inhibitors would show the glioma brains 
shrinking back to a moderate normal size, and also have the glial cell population decrease 
(Figure 2). A negative effect of the drug would either show no change from the original 
or a sharp increase in glial cells and a larger abnormal brain lobe shape (Figure 2). The 
inhibitors that proved to show success will be tested at different concentrations and also 

































Figure 10. The seven-step protocol followed when testing both the Tyrosine Kinase Inhibitors 
and TMZ on the Drosophila glioma model. 


































Figure 11. These are results used to help determine if a specific tyrosine kinase 
inhibitor showcases suppression, enhancement, or no change in tumor size and 
shape when compared to the control groups. The control group is a normal, healthy 
fly brain.    




Combinatorial Drug Screen 
Given that both TMZ and the tested Tyrosine Kinase Inhibitors showed positive results 
when used on the Drosophila glioma model separately, they went on to be further tested 
when used in combination. The five successful tyrosine kinase inhibitors were tested with 
the control value of TMZ (3mM) at a set value of 300μM on Repo GFP and Pteni; 
Rasv12x Repo GFP. The five tyrosine kinase inhibitors were A4, A9, B4, B6, and B9. The 
300μM was chosen to test for the initial success of TMZ combined with the kinase 
inhibitors. These set values of TMZ and kinase inhibitors were added to the larvae’s food 
by protocol, and the success of the screen was analyzed the same way the initial TMZ 
screen was. On day-three 50 larvae were added into the drug concentrated food, and it 
was starting on day-five that the larvae could begin to get analyzed and counted. By 
counting the amount of small, medium, large tumors and possible alive flies present, the 
combination was determined to be successful at this concentration range.  
 
The most successful of these combinations was A9 (300μM) + TMZ (3mM). To 
determine if A9 would be more successful at a different concentration range, it was tested 
by changing the concentration using a log scale. These log scale concentrations tested 
were 10μM, 30μM, 100μM, and 300μM. Over the course of several weeks these 
combinations were tested and analyzed by counting the number of different tumors 
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Chapter 3  
Results  
Tyrosine Kinase Results  
The primary drug screen that has looked solely at the effectiveness of Tyrosine Kinase 
Inhibitors has been an entire group effort between students in Dr. Kango-Singh’s lab. 
This is still an ongoing project as well to continue to determine tyrosine kinase inhibitors 
that show suppression in our Drosophila glioma model. Like stated earlier, the results of 
tyrosine kinase inhibitors by themselves are tested through dissection and mounting of 
the larval brains. From this analysis and comparing images of the brains, it was 
determined there were six inhibitors that showed strong suppression effects on our tumor 
model. These drugs were: P1A4, P1A9, P1B4, P1B6, P1B9 and P1G10. The results from 
one of these successful drugs, P1G10, is pictured in Figure 12. P1G10 is determined to 
show suppression due to that both brain lobes and the ventral nerve cord (VNC) 
decreased relatively close to the control, and the glia cell population has not increased. 
All other tyrosine kinase inhibitors listed above also followed a similar suppression trend 











































Figure 12. Results from our glioma tumor being tested with Tyrosine Kinase Inhibitor 
P1G10. Results were looked at over the course of three days to determine effectiveness. 
Over the course of the analysis period P1G10 continued to show strong suppression results 
of the tumor. 
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Initial Temozolomide Screen  
The initial screen of TMZ was done in order to test the concentration that it works best at 
in our Drosophila glioma model. TMZ was tested using a log scale from values 10-
1000μM, and then an additional 3mM and 5mM. To analyze the effects that TMZ has on 
the Drosophila glioma model, mounting and dissection will not take place. Given that 
TMZ is a DNA alkylating agent, most of the larvae will not progress into the alive fly 
stage but will be halted in their growth at the pupal stage. The growth arrest phenotypes 
were categorized based on the tumor size which was tracked by the expression of GFP. 
The pupae were categorized as small, medium, and large tumors and the effect of 
particular concentration of TMZ was tested.  
 
The different tumor sizes along with the control group can be seen in Figure 13. A small 
tumor is observed when the larvae progresses all the way to producing red eyes and 
wings but does not progress all the way to hatching. A medium tumor takes up more a 
presence within the larvae but has not completely taken over, as what would be seen in a 
large tumor. A large tumor completely takes over the larvae and produces necrotic spots 
along the pupae. With a large tumor it looks as if a larva never even formed within the 
pupal casing, but instead always remained empty. The TMZ concentration with the 
largest amount of small tumor larvae, along with the larvae that show the greatest vitality, 
will be seen as the most successful concentration of TMZ.  
 
Another aspect that was analyzed when determining the successful TMZ concentration 
was the vitality of the larvae after treatment to the drug. TMZ effectiveness was tested by 
adding fifty larvae from each stock to every concentration tested. The larvae that would 
showcase the most vitality after being treated would lend to it being determined a 
successful concentration of treatment. High vitality was determined by the greatest 
number of larvae that came up from food concentrated with TMZ. If only ten out of fifty 
larvae come up from the food after treatment, this would showcase low vitality given a 
majority of larvae died due to the drug concentration. This death could either occur from 
the concentration being too low to have an effect on the glioma, or that it was too high 
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and was cytotoxic. The concentration of TMZ that shows the most success will go on to 
be used as the control value for the combinatorial drug screens between TMZ and the 



























































Figure 13. Images of a small, medium, and large tumor after treatment with the effective 3mM 
concentration of TMZ. The small tumor is identified by its presence of both wings and eye disks 
within the pupal casing. Large and medium tumors are distinguished based on the large tumors 
having necrotic spots presence and also less larvae present in the case. 
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Testing the effects of Temozolomide on glioma growth 
The effective control concentration of Temozolomide when used on the Drosophila 
glioma model (Pteni; Rasv12x Repo GFP) was determined to be 3mM. This was 
determined due to the 3mM concentration having the largest number of alive flies (9) and 
small tumors (7) present after treating with the drug. Given that other concentrations 
tested also had a large number of small tumors present, 3mM was selected due to the 
large number of alive flies that hatched over the time of observation. Alive flies are 
highly uncommon when in treatment with TMZ due to TMZ acting as an alkylating 
agent, so the presence of them gains immense interest. The least of effective 
concentration of TMZ was 1.5mM, given that this had the largest number of large tumors 
present (17) after treatment and no live flies hatching from their pupal casing. The results 
from the different concentrations can be viewed in Table 1. Images of an example of the 












































Table 1: The different tumor counts in the Drosophila after treatment with different concentrations of 
TMZ. It was through these results and the large amount of both small tumor and alive flies seen at 
the 3mM range that made it be chosen as the control value for future experiments containing TMZ 
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Tyrosine Kinase and Temozolomide Combinatorial Results  
In the combinatorial research there was a total of five different tyrosine kinase inhibitors 
tested along with the concentration value of 3mM TMZ. The five tyrosine kinase 
inhibitors that went on to be further tested at the 300μM concentration level were: A4, 
A9, B4, B6, and B9. Out of these combinations A4(300μM) + TMZ(3mM) was one 
combination that showed significant suppression of the tumor. This suppression was 
determined based off the significant number of small tumors and alive flies present after 
addition to the drug. As seen in Table 2, there was a total of 9 small tumors and 3 alive 
flies present. Although there was still a sizable number of large tumors present (15 total), 
it was the fact that there were alive flies that hatched that kept promise of success of this 
specific combination. Another combination that stood out as being a potential successful 
suppressor was B9(300μM) + TMZ(3mM). Looking at both Table 2 and Graph 1, the 
most substantial result from this combination is the large number of alive flies that 
hatched out of the treated fifty. There was a total of ten alive flies that hatched, which is 
the most out of any other combination tested. Given that both of these showed substantial 
results, it was the A4(300μM) + TMZ(3mM) combination that was selected first to go 
through a more thorough testing of different concentrations that might be more effective 

































 Pteni; Rasv12 x Repo Combinatorial Drug Results of Number of Tumors 
Present with Various Tyrosine Kinase Inhibitors 
 
Drug Type Small Tumor Medium Tumor  Large Tumor Alive Flies  
A4 (300μM) + 
TMZ (3mM) 
9 7 19 2 
A9 (300μM) + 
TMZ (3mM) 
9 10 15 3 
B4 (300μM) + 
TMZ (3mM) 
2 9 12 8 
B6(300μM) + 
TMZ (3mM) 
17 3 15 3 
B9 (300μM) + 
TMZ (3mM) 
12 9 9 10 
Table 2. This table is showing the different number of small, medium, and large tumors present in 
the larvae after each individual concentration of Tyrosine Kinase Inhibitor (300nm) + TMZ (3mM) 
was added. The total number of larvae added to each combination was 50 and the type of tumor was 
counted and recorded in the table above to help track both the success of the combination and 
vitality of the drug. 






















Graph 1. This graph shows the results from the different tyrosine kinase inhibitors 
when combined with 3mM TMZ. This graph was creating using the values in Table 2. 
Looking at the difference in size of tumor it was both A9 and B9 that showcased the 
most success as a tumor suppressor when aligned on a side by side graph like above.  
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Various concentrations of A9 + Temozolomide (300mM) Results  
To further test the success that the Tyrosine Kinase Inhibitor A9 + TMZ could have, it 
was selected and observed separately using different concentration values. The 
concentrations selected were based on a log scale and the same amount of fifty larvae 
were added to each. Looking at the table and graph below there were significant results 
from the data collection. One of these results was the high success seen in the 
concentration value of 100μM versus the originally tested 300μM. In the 100μM 
concentration value there is a large number of small tumors present (18) and a significant 
number of alive flies (8) when compared to the medium and large tumor presence at this 
concentration (6 and 5, respectively) as seen in Table 3.  
 
Another concentration that showed promise due to the substantial amount of suppression 
present was the A9 (10μM) + TMZ (3mM). Looking at Graph 2, it is this combination 
that shows the largest number of small tumors present when compared to the other three 
concentrations of A9 tested. Given this high number of large tumors present, it shows 
potential to be looked into through further testing. When compared to the results of A9 
(100μM) + TMZ (3mM) that were described earlier, the 10μM concentration 
combination still did not succeed the effects of it due to the very low number of alive 
flies present and not significant halting of the tumor growth. The presence of alive flies at 
these concentrations hold much more importance in showing the effects it has on the 
tumor than the number of small tumors present. Taking this into consideration, it is the 
large number of alive flies that hatched (as seen in the 100μM combination) that proves 
more success than a large number of small tumors (as seen in the 10μM).  
 
The concentration that showed the least amount of suppression was at the 300μM level, 
which was a significant result given it was this concentration value that showed the most 
promise in the original combinatorial study. This combination value of A9 (300μM) + 
TMZ (3mM) was determined to have the least amount of suppression compared to the 
others based off of it having the highest number of large tumors present when compared 
to both the small, medium, and alive flies at its same concentration value. With this 
leading amount of 15 large tumors present as seen in Graph 2, it was deemed that the 
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combination was not as successful as originally thought it was. This decrease in success 
is hypothesized to be due to the amount of 300μM being too high of a concentration for it 
to show any significant results. The concentration of drug starts to either cause 
cytotoxicity to the larvae or the concentration is too large for it to produce a successful 
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 Pteni; Rasv12 x Repo Results of Number of Tumors from A9 at 
various combinations + 3mM TMZ  
Drug Type  Small Tumor Medium Tumor Large Tumor  Alive Flies 
A9 (10μM) + TMZ 
(3mM) 
27 7 2 1 
A9 (30μM) + TMZ 
(3mM) 
11 2 8 9 
A9 (100μM) + TMZ 
(3mM) 
18 6 5 8 
A9 (300μM) + TMZ 
(3mM) 


















Table 2. This table is showing the different number of small, medium, and large tumors 
present in the larvae after each individual concentration of Tyrosine Kinase Inhibitor A9 + 
TMZ (3mM) was added. The total number of larvae added to each combination was 50 and 
the type of tumor was counted and recorded in the table above to help track both the success 
of the combination and vitality of the drug.  
 





















Graph 1. This graph shows the results from the tyrosine kinase inhibitor A9 at different 
concentrations on a log scale when it is combined with the control value of TMZ at 3mM. This 
graph was creating using the values in Table 3. Looking at the difference in size of tumor it was 
the A9 (100μM) that showcased the most success.  
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Conclusion  
In conclusion we found that there were significant combinatorial effects when both the 
Tyrosine Kinase Inhibitor and Temozolomide were added to treat glioblastoma. With the 
poor prognosis that Glioblastoma has, these results are significant in the possibility of 
helping reduce these deathly diagnoses. One of the initial takeaways from these results is 
the promise that TMZ by itself showed in our Drosophila model. Given that TMZ is not 
supposed to have any alive flies hatch due to it acting as a DNA alkylating agent, it was 
surprising to see so many appear at the 3mM range. This result could be due to the 
amount of TMZ treating the glioma was not enough for it to become lethal to larvae, 
while at the same time not allowing all of the DNA to become alkylated. The presence of 
alive flies was something that carried on into the other experiments containing TMZ, 
which helped support the validity that the alive flies at 3mM were not an outlier. It was 
the effectiveness of TMZ alone that was seen in our Drosophila glioma model that helped 
further support its effectiveness as a chemotherapy drug, which is how it is currently 
being used in treatment of glioblastoma.  
 
The effective concentration of TMZ (3mM) was combined with the Tyrosine Kinase 
Inhibitors that proved successful throughout past experiments in order to determine if 
tumor suppression could be seen in combination of drugs. The five successful tyrosine 
inhibitors were initially tested at a control value of 300μM when in combination with the 
3mM TMZ. The findings from these results showed that there were significant 
suppression effects in some of the combination of Tyrosine Kinase Inhibitors and TMZ. 
It was in the combinations of A9 (10μM) + TMZ (3mM) and B9 (10μM) + TMZ (3mM) 
that the most impressive results were found. Both of these concentrations not only had a 
significant number of small tumors present when in comparison to the medium and small 
tumors, but they also had a noticeable number of alive flies’ present. Although the high 
presence of small tumors does lead to the combination being a tumor suppressor, the 
presence of alive flies holds more weight when it comes to analyzing results. This is due 
to it being relatively uncommon in the treatment of TMZ, so the presence of them leads 
to the drug treating the glioma enough to allow the larvae to fully hatch. When looking at 
the combinations, the high frequency of alive flies could be due to the positive effect the 
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Tyrosine Kinase Inhibitor has on suppressing the glioma, and this effect could override 
the alkylating effect of the TMZ present. Also, TMZ alone at 3mM showed a high 
percentage of alive flies, so this concentration from past experiments is not known to 
fully alkylate all the DNA present in the larvae. It was the success that was found 
throughout this combinatorial experiment that led to further testing with these two 
chemotherapy drugs.  
 
Isolating A9 at different combinations with TMZ (3mM) also showed significant results 
in the suppression of the glioma tumor. A9 was selected for isolation due to the strong 
tumor suppression results it showed in the earlier experiment discussed above. Looking at 
the results, it was clear to see that the initially tested 300μM of Tyrosine Kinase Inhibitor 
was not the best concentration value when combined with the control TMZ. Looking at 
Graph 2 it is clear to see the varying results across the four tested concentration ranges. 
Given that it was tested on a log scale there is some variability between all of the values, 
but the most effective concentration tested came to be the A9 (100μM) + TMZ (3mM). 
This was a lesser concentration than the 300μM initially tested, which leads to the 
conclusion that A9 at a lesser concentration is more effective than at larger ones 
(300μM<x). By determining the concentration range that this specific drug works best, 
future testing could be done to help narrow the specific range down even further. 
 
When studying the Tyrosine Kinase Inhibitors in the primary drug screen there were over 
seventy drugs beings tested on the Drosophila glioma model. The need to conduct this 
blind study on the variety of different tyrosine kinase inhibitors was due to each 
activating a different protein pathway in order to exert their effect on the tumor. Looking 
at the results it was clear to see that each inhibitor tested did not show the same results, 
but instead showed a range of suppression and enhancement on the glioma. These results 
allowed for it to be further confirmed that although a category of treatment drugs have 
the same end result (i.e. adding a phosphate group), they do not activate the same 
pathways to get there. This activation of different pathways allows for different effects to 
be placed on the tumors which creates a wide variety of choices to choose in treatment of 
an individual suffering glioblastoma. To narrow down which protein pathways are 
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specifically activated in the successful suppression tyrosine kinase inhibitors tested, 
Western Blotting must be run. Western Blotting will be able to show the exact proteins 
that are activated in the pathway, and these results can be compared to other drugs that 
also use the same pathway. This comparison will allow for a quicker selection of drugs to 
be tested and a connection between a wider range of chemotherapy drugs.  
 
Finally, given that this was a primary drug screen to test the initial effects of both 
tyrosine kinase inhibitors and TMZ on glioblastoma, there is further testing needing to be 
done to determine the overall effectiveness on other model organisms. The results of 
these combinatorial results showed success in our Drosophila glioma model, which 
leaves the question open if these results can be replicated in other systems. These 
combinations found to be successful in reducing the tumor in the fruit fly are worth 
testing in other organisms (i.e. mice). Mice are a helpful model in determining the 
success a drug would have in humans due to them sharing 85% of its genomes with 
humans and their genes being able to be added or removed easily for further testing (Why 
Mouse Matters, 2010). If the results are replicated in a different organism’s system, then 
more credibility is added to the ability of the drug to act as a suppressor and therefore 
would show more promise to continue testing into clinical trials. Clinical trials are the 
last in drug testing to determine the overall success. If our combinatorial chemotherapy 
treatment makes it to clinical trials and continues to show suppression in human models, 
this shows great promise and confirms the success of this treatment in suppression 
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